Publications by authors named "Miguel Lopez-Esteban"
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a transformative treatment for aggressive B-cell lymphomas (ABCL), However, about half of patients relapse, most of them early. This study investigates the detection of CAR copies in circulating cell-free DNA (cfDNA) as a potential predictive biomarker of early relapse (<6 months) to improve patient management. In this research, we have consecutively selected 73 ABCL patients treated with anti-CD19 CAR T-cells, analysing CAR levels in peripheral blood and other clinical variables.
View Article and Find Full Text PDFArticle Synopsis
- * A study involving 781 untreated stage A CLL patients compared five different risk scoring methods to see which best predicted disease progression, also assessing the impact of including the IGHV2 subset as a poor prognostic factor.
- * All five risk scores performed similarly in identifying low to high-risk patients, with CLL-IPI showing the best results, and findings indicate that incorporating IGHV2 could enhance the accuracy of these risk assessments.
Visfatin/extracellular-nicotinamide-phosphoribosyltranferase-(eNampt) is a multifaceted adipokine enhanced in type-2-diabetes and obesity. Visfatin/eNampt cause in vitro endothelial dysfunction and vascular inflammation, although whether the same effects are achieved in vivo is unknown. Toll-like receptor-4 (TLR4), a main surface pattern recognition receptor of innate immune system is a potential target for visfatin/eNampt.
View Article and Find Full Text PDF